Early tumour response assessment may avoid serious immune‐related adverse events in nivolumab and ipilimumab combination therapy for stage IV melanoma-Reference-Cited by-同舟云学术

Early tumour response assessment may avoid serious immune‐related adverse events in nivolumab and ipilimumab combination therapy for stage IV melanoma

Published:2021-12-21 Issue: Volume: Page:
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Maeda T.¹^ORCID,Hiura A.¹,Uehara J.¹,Toyoshima R.¹,Nakagawa T.¹,Yoshino K.¹

Affiliation:

1. Department of Dermatologic Oncology Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.20879

Reference9 articles.

1. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

2. Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma

3. Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review

4. Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review

5. Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: a systemic review

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab;Journal for ImmunoTherapy of Cancer;2024-08

2. New insights into programmed cell death protein 1 blockade-associated cutaneous immune-related adverse events;British Journal of Dermatology;2023-07-20

3. Combined use of nivolumab and ipilimumab in Japanese patients with melanoma: a multicentre retrospective study of 111 cases;British Journal of Dermatology;2023-04-05

4. Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis;Frontiers in Pharmacology;2022-09-05